A Randomized Controlled Study of the NEURESCUE Device as an Adjunct to Advanced Cardiac Life Support

Launched by NEURESCUE · Jan 20, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new device called the NEURESCUE, which is designed to help patients who have suffered a cardiac arrest. The NEURESCUE device is a special balloon catheter that is inserted through a blood vessel in the leg to redirect blood flow to the heart and brain, enhancing blood circulation quickly within one minute of being used. The study aims to compare the standard emergency treatment known as Advanced Cardiovascular Life Support (ACLS) with the combination of ACLS and the NEURESCUE device to see which approach works better for patients in cardiac arrest.

To be eligible for this trial, participants must be between 18 and 80 years old, have experienced a witnessed cardiac arrest, and have received CPR within seven minutes after the arrest. It's important that CPR is ongoing for less than 40 minutes at the time of enrollment and that the heart rhythm is one that doesn’t respond to shocks. Unfortunately, those with certain conditions, such as a traumatic cardiac arrest or a terminal illness, cannot participate. If you or a loved one is eligible and chooses to participate, you will be closely monitored during the study to ensure safety and collect important information about how well the NEURESCUE device works in emergency situations.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥18 and ≤80 years
• • Witnessed arrest
• • CPR initiated within 7 min of arrest
• • CPR time less than 40 min at enrollment
• • Non-shockable rhythm
• Exclusion Criteria:
• • Traumatic cardiac arrest
• • Known pregnancy
• • Known terminal disease
• • Known do-not-attempt-CPR order
• • Known opposition to study participation